hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8. Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.
As in World War I, white Rhodesians volunteered for the forces readily and in large numbers. Over 2,700 had come forward before the war was three weeks old. Somewhat ironically, the Southern Rhodesian recruiters' main problem was not sourcing manpower but rather persuading men in strategically important occupations such as mining to stay home. Manpower controls were introduced to keep certain men in their civilian jobs. The SRAF accepted 500 recruits in the days following the outbreak of war, prompting its commander Group Captain Charles Meredith to contact the Air Ministry in London with an offer to run a flying school and train three squadrons. This was accepted. In January 1940 the Southern Rhodesian government announced the establishment of an independent Air Ministry to oversee the Rhodesian Air Training Group, Southern Rhodesia's contribution to the Empire Air Training Scheme (EATS). Huggins set up a Defence Committee within the Cabinet to co-ordinate the colony's war effort in early 1940. This body comprised the Prime Minister, Tredgold and Lieutenant-Colonel Ernest Lucas Guest, the Minister of Mines and Public Works, who was put in charge of the new Air Ministry. About 1,600 of the colony's whites were serving overseas by May 1940 when, during the Battle of France, Salisbury passed legislation allowing the authorities to call up any male British subject of European ancestry aged between 19 and a half and 25 who had lived in the colony for at least six months. The minimum age was reduced to 18 in 1942.
=== All-cause mortality === Two meta-analyses concluded that as a dietary supplement, vitamin E neither improved nor impaired all-cause mortality. A meta-analysis of long-term clinical trials reported a non-significant 2% increase in all-cause mortality when alpha-tocopherol was the only supplement used. The same journal article reported a statistically significant 3% increase for results when alpha-tocopherol was used in combination with other nutrients (vitamin A, vitamin C, beta-carotene, selenium).
Sources: en.wikipedia.org
Homologous recombination OB-fold protein is a protein which in humans is encoded by the gene HROB (previously C17orf53). It is involved in the repair of DNA, and is most highly expressed in the digestive system and female reproductive system. Pathogenic variants have been associated with female reproductive system dysfunction, including premature menopause and ovarian dysgenesis. Neighboring genes of HROB are that of RNU6-131, RNA U6 Small Nuclear 131 Pseudogene, and ASB16, Ankyrin Repeat And SOCS Box Containing 16. HROB has been observed to be expressed ubiquitously across almost all tissue types of the body, but with highest expression found in the duodenum and fallopian tubes, while in the brain there was little region specificity. However, inconsistencies between antibody staining and RNA expression make interpretation of these results difficult.
Technetium, with atomic number Z = 43, is the lowest-numbered element in the periodic table for which all isotopes are radioactive. The second-lightest exclusively radioactive element, promethium, has atomic number 61. Atomic nuclei with an odd number of protons are less stable than those with even numbers, even when the total number of nucleons (protons + neutrons) is even, and odd numbered elements have fewer stable isotopes. The most stable radioactive isotopes are technetium-97 with a half-life of 4.21±0.16 million years and technetium-98 with 4.2±0.3 million years; current measurements of their half-lives give overlapping confidence intervals corresponding to one standard deviation and therefore do not allow a definite assignment of technetium's most stable isotope. The next most stable isotope is technetium-99, which has a half-life of 211,100 years. Thirty-four other radioisotopes have been characterized with mass numbers ranging from 86 to 122. Most of these have half-lives that are less than an hour, the exceptions being technetium-93 (2.75 hours), technetium-94 (4.88 hours), technetium-95 (19.26 hours), and technetium-96 (4.28 days). The primary decay mode for isotopes lighter than technetium-98 (98Tc) is electron capture, producing molybdenum (Z = 42). For technetium-98 and heavier isotopes, the primary mode is beta emission (the emission of an electron or positron), producing ruthenium (Z = 44), with the exception that technetium-98 and technetium-100 can decay both by beta emission and electron capture.
21% of all participants were children. No studies directly compared insulin degludec with NPH insulin. In the studies comparing insulin degludec to insulin detemir (2 RCTs) and insulin degludec to insulin glargine (4 RCTs), no clinically relevant difference was found for the outcomes of all-cause mortality, health-related quality of life (QoL), severe hypoglycemia, non-fatal myocardial infarction/stroke (NFMI/NFS), severe nocturnal hypoglycaemia, serious adverse effects (SAE) and Glycated haemoglobin A1c (HbA1c).
The isotope effect associated with transamination also makes amino acid nitrogen isotopes a useful tool to study the structure of food webs. Repeated transamination by consumers results in a predictable increase in the abundance of 15N as amino acids are transferred up food chains. Together, these application, among others in ecology, demonstrate the utility of stable isotopes as tracers of environmental processes that are difficult to measure directly.
Sources: en.wikipedia.org
This section has also been interpreted by some doctors, most notably the authors of a commentary article published in the Journal of the American Medical Association in 2005, as meaning that prescribing HGH off-label may be considered illegal. And some articles in the popular press, such as those criticizing the pharmaceutical industry for marketing drugs for off-label use (with concern of ethics violations) have made strong statements about whether doctors can prescribe HGH off-label: "Unlike other prescription drugs, HGH may be prescribed only for specific uses. U.S. sales are limited by law to treat a rare growth defect in children and a handful of uncommon conditions like short bowel syndrome or Prader-Willi syndrome, a congenital disease that causes reduced muscle tone and a lack of hormones in sex glands." At the same time, anti-aging clinics where doctors prescribe, administer, and sell HGH to people are big business. In a 2012 article in Vanity Fair, when asked how HGH prescriptions far exceed the number of adult patients estimated to have HGH-deficiency, Dragos Roman, who leads a team at the FDA that reviews drugs in endocrinology, said "The F.D.A. doesn't regulate off-label uses of H.G.H. Sometimes it's used appropriately. Sometimes it's not."
In mid-1995, the US government tried to reduce the supply of methamphetamine precursors to disrupt the market of this drug. According to a 2009 study, this effort was successful, but its effects were largely temporary. In the six years from 2000 to 2006, the US spent $4.7 billion on Plan Colombia, an effort to eradicate coca production in Colombia. The main result of this effort was to shift coca production into more remote areas and force other forms of adaptation. The overall acreage cultivated for coca in Colombia at the end of the six years was found to be the same, after the US Drug Czar's office announced a change in measuring methodology in 2005 and included new areas in its surveys. Cultivation in the neighboring countries of Peru and Bolivia increased, some would describe this effect like squeezing a balloon. Richard Davenport-Hines, in his book The Pursuit of Oblivion, criticized the efficacy of the war on drugs by pointing out that "10–15% of illicit heroin and 30% of illicit cocaine is intercepted. Drug traffickers have gross profit margins of up to 300%. At least 75% of illicit drug shipments would have to be intercepted before the traffickers' profits were hurt." Alberto Fujimori, president of Peru from 1990 to 2000, described US foreign drug policy as "failed": "For 10 years, there has been a considerable sum invested by the Peruvian government and another sum on the part of the American government, and this has not led to a reduction in the supply of coca leaf offered for sale.
Unlike most modern eggs, many non-avian dinosaur eggs had a rough texture formed by nodes and ridges ornamenting the surface of their shell. This is predominant in Cretaceous dinosaur eggs, but very rare in eggs from the Jurassic or Triassic. Because of the lack of modern analogues, the purpose of eggshell ornamentation is unknown, but many functions have been proposed. Possibly, they provided extra strength to the eggshell without having pore canals too long for adequate gas exchange. They could also have helped keep substrate away from the pore openings of eggs that were buried, but modern turtles and crocodylians which bury their eggs have smooth eggshells, so this adaptation is not necessary for animals which bury their eggs. Another hypothesis, proposed by R. M. Mellon in 1982 in his senior thesis at Princeton University, is that the ridges and nodes would have formed pathways for gas to flow across the surface of the eggshell, preventing accumulation of too much CO2 and aiding the flow of oxygen and water vapor. Since it varies from egg to egg, the texture of an eggshell's ornamentation is useful for classification. Six types of ornamentation were catalogued by Carpenter in 1999:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.